Tag Archives: technology

Hot Investor Mandate 1: Japanese CVC with USA Offices Invests in Novel Pharmaceutical, Medical Device, and Digital Health Technologies

24 May

A corporate venture arm of a diversified business based in Tokyo is focused on investing in various sectors, including healthcare. The team is based in offices in both the West and East Coast. The fund has an evergreen structure looking to allocate between $1-$3 million per deal initially and up to $5 million over the life of the investment. The firm is seeking to invest in approximately 2-4 companies over the next 12 months and are open to investing in companies across the globe.

Sectors of interest include: pharmaceuticals, medical device and digital health. Therapeutic and product areas of interest include: Pain, critical care, musculoskeletal disease, kidney disease, DDS, patient monitoring technologies, bioprocessing technologies, digital therapeutics. The firm is open to all stages of investment, with a general preference toward companies with at least some early clinical data.

The firm invests in private companies and is willing to work with all types of management teams including incomplete teams. The firm generally requests at least an observer seat following investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 3: California-Based VC Seeking to Invest in Therapeutic Technologies that Solve Problems Within Genetically Driven Diseases

17 May

A California-based firm backed by a number of well-known global funds is actively seeking investment opportunities. The firm prefers to be the first institutional investor in a company, and is typically an active, lead investor (often the sole investor). The firm typically invests in 5 opportunities per year.

The firm focuses on genetic drivers of disease, and therefore only invests in treatments for monogenic diseases or genetically-driven cancers. The firm is only interested in treatments that elicit a disease-modifying response; treatments that target symptoms of monogenic diseases are not of interest. Therapeutics must have a clearly-defined mechanism of action. The firm usually invests at the preclinical stage, up to 18 months prior to IND, but is open to later stage candidates (including clinical).

The firm focuses on individual products, not technology platforms. The firm typically houses each single asset in its own discrete subsidiary. The firm has internal expertise in medicinal chemistry, biology, and clinical trials, with personnel having significantly contributed to 30+ INDs and 10+ approved drugs. The company will often leverage internal expertise for subsidiaries, and can also assist with recruiting.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 1: Large VC Firm Focused on Data-Driven Life Science Technologies, from Devices to Computational Drug Discovery

5 Apr

A venture capital firm with offices in California backs entrepreneurs applying deep and differentiated technology to transform giant industries. The firm focuses on seed and series A investments and has raised multiple funds to date, with over $1B AUM. The firm usually makes seed investments in the range of $250K – $1M and venture-stage investments from $1M-$4M and may use both convertible notes or straight equity. The firm may lead or co-invest in a syndicate and looks to add unique value to entrepreneurs with a strong Equity Partner network, operational experience and technical background.

The firm invests in several verticals and is focused on deep technologies such as AI, advanced materials, quantum computing, etc. In the healthcare space, the firm is focused on the entire continuum including computational drug discovery, AI-driven diagnostics, better/faster clinical trials and technologies used by payers and providers to better understand and manage risk and drive better outcomes. The common theme is that the startup’s underlying technology be novel and data-driven. The firm is also interested in synthetic biology. The firm does not invest in biopharma or traditional medical devices/diagnostics with a standard regulatory pathway.

The firm requires that startups have some type of proof-of concept and traction. The firm prefers experienced/proven management teams and entrepreneurs that are introduced through the firm’s network. The firm typically seeks a board seat when leading an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 3: Technology Firm Establishes New Venture Fund for Investing in Early-Stage Digital Health Companies Globally

5 Apr

An operating group of a global public technology firm with an $18B market cap. The group began its venture portfolio in 2018 with investments in B-to-B software companies targeted at specific vertical markets such as healthcare. The fund invests $0.5M – 1M per company and is seeking companies raising seed to Series B rounds. The company is seeking 5 – 10 new investments to build their initial portfolio. The company prefers companies based in Canada, though as the parent firm is located in the US, UK, EU, and AU, the fund is open to invest globally.

The company is seeking healthcare IT, and they are particularly investing in technologies with a software component. The firm prefers commercial-stage companies, though is open to looking at clinical-stage companies as well. The company is indication agnostic.

The company will help companies fill management team positions, if necessary. The company prefers companies that are generating $100K – 3M in annual revenue.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

RESI on MaRS – Spotlight Your Technology in the RESI Innovation Challenge

2 Feb

By Shaoyu Chang, MD, MPH, Director of Research & Asia Business Development Liaison, LSN

Shaoyu 10*10

LSN is gearing up for the upcoming Redefining Early Stage Investments (RESI) Conference in Toronto’s MaRS Discovery District, and we’re seeking fundraising CEOs with the most promising early stage healthcare technologies to showcase in the RESI Innovation Challenge on April 4, 2017.

LSN’s scientific team is preparing to review the RESI Innovation Challenge applications from therapeutics, medtech, diagnostics and healthcare IT companies around the globe. All applicants will be vetted based on not only the quality of the company’s scientific work, but also the strength of the management team and how well-positioned the company is to receive investment.

On April 4, 2017, each attendee will receive “RESI Cash” to allocate to the entrepreneurs whose technologies they expect will be most influential. The capital invested will be tallied up and the top three winners will receive prizes and be featured in our RESI newsletter recap that will go out to LSN’s 20,000 newsletter readership. See below for the previous RESI Innovation Challenge first place winners – a diverse group of startups from every area of the life sciences.

What makes the RESI Innovation Challenge so valuable?  We’ve included a few words from previously successful participants below, but in short, being part of the Innovation Challenge provides startups with a new way to get attention and start dialogues with the investors who attend RESI. Participants can share their message all day in the exhibit hall, with their Innovation Challenge display providing a starting point for a meaningful conversation about the opportunity.

apply-button

APPLICATION DEADLINE: FEB. 15, 2017

Here is what our previous winners are saying about the RESI Innovation Challenge:

DSC00392

“It was an absolute pleasure to participate in the RESI conference held at MaRS in Toronto. The unique structure of the conference facilitated creating new relationships with potential investors and partners. In particular, the Innovation Challenge pushed us to introduce ourselves to new people, which will be useful as we look towards a future financing round. I definitely recommend the RESI conferences to entrepreneurs seeking financing in the bio / health space.”
 
– Raymond Shih, President, Co-Founder, QoC Health
3rd Place, RESI on MaRS, June 23, 2016

“I love the RESI Innovation Challenge because it is a great way to give our pitch to practice it and try to obtain a scarce resource from these investors. Practicing with these investors is a great way to build relationships and continue that on to the real investment conversations.”

– Niko Skievaski, Co-Founder, Redox

1st Place, RESI@TMCx, June 8, 2015

02

“The RESI Innovation Challenge is a really good opportunity to meet investors and other companies in the space.  It’s a good showcase to reach that audience.”

– Jessica Ching, CEO, Eve Medical

2nd Place, RESI San Francisco, January 12, 2016

“The RESI Innovation Challenge is a unique way to pitch, and provides a great opportunity to see what other companies are doing in the industry, while allowing you to meet with potential investors and strategic partners outside of the partnering meetings.”

– John Connolly, VP Corporate Development, Rna Diagnostics

1st Place, RESI Boston, September 16, 2015

01

“RESI offers small companies like GeneSegues a direct line to potential partners and potential investors in a small setting conducive to relationship building and conversation. The Innovation Challenge was a particularly great way to introduce our company to a broader audience than I could meet with personally which allowed us to leverage the showcasing of our technology more efficiently.”

-Laura M. Brod,Chief Executive Officer,GeneSegues Therapeutics

-1st Place, RESI @TMCx, April 11, 2016

Compelling New Technology Startups Selected, RESI X Innovation Challenge

18 Aug

By Dennis Ford, CEO of LSN; Creator of RESI Conference Series

As RESI comes back to Boston for its 10th conference, we’re excited to announce the early stage life science companies that will be participating in the event’s RESI Innovation Challenge.

The 30 participating companies have been hand-selected by LSN’s scientific review committee based on the innovative nature of their core technology and how well-positioned each is to capitalize on their respective market opportunities. The selected companies, two thirds of which have received funding from various NIH institutes, cover all corners of the life science domain including therapeutics, medtech, diagnostics and digital health.

Therapeutics

ADT-500t Duophos-500t Laurent-Pharmaceuticals-500t
Mitochondrial-Substrate-Invention-500t Novoron-500t PrimeVax-500t
SignalRx-500t

Technology Platform

Diagnostics

Medical Device

Digital Health

RESI on MaRS: Spotlight Your Technology in the MaRS HealthKick Innovation Challenge

21 Apr

By Jay Doherty, Marketing Manager, LSN

jay

LSN is gearing up for our first international RESI event in Toronto on June 23rd, and we’re seeking the most promising early stage healthcare technologies to showcase in the MaRS HealthKick Innovation Challenge. Successful applicants will be showcased in an exhibition-style format throughout the full-day conference.

LSN’s internal scientific review board will choose the top 30 applicant companies to present their technologies. Presenters will gain exposure to investors and potential partners by showcasing their companies and products in a poster board format in the RESI Exhibition Hall. Unlike traditional 5- to 15-minute pitch presentations, which don’t provide any real one-on-one interaction or actionable feedback from investors, the MaRS HealthKick Innovation Challenge enables executives to share their pitch directly with attendees, which can generate more in-depth and frequent conversations with potential investors throughout the event.

To add some friendly competition to the mix, LSN invites all attendees to participate in the MaRS HealthKick Innovation Challenge as virtual investors. At the start of the day, each attendee will receive “RESI Cash” to allocate to the entrepreneurs whose technologies they expect will be most successful. The capital invested will be tallied up at the end of the day, and the top three winners will receive prizes and be featured in our RESI newsletter recap that will go out to LSN’s 23,000 newsletter readership.

Previous RESI Innovation Challenge winners include:

Please apply to the MaRS HealthKick Innovation Challenge today to put the spotlight on your company. We look forward to seeing you take part in our first RESI on MaRS!

MARS-Innovation-Challenge